Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
J Infect
; 89(3): 106228, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38996818
ABSTRACT
OBJECTIVES:
To estimate vaccine effectiveness (VE) and duration of protection of single primary and booster immunisation with meningococcal C (MenC) and ACWY (MenACWY) conjugate vaccines in preventing MenC invasive meningococcal disease (IMD).METHODS:
We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12-23 months for primary and 6-18 years for booster immunisation (last search 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO CRD42020178773).RESULTS:
We identified 10 studies. Two studies reported VE of primary immunisation with MenC vaccines ranging between 90% (74.9 - 96.1) and 84.1% (41.5 - 95.7) for periods of 2 and 7 years, respectively. Eight studies reported immunogenicity of primary immunisation with MenC and/or MenACWY vaccines, of which two reported -in addition- on booster immunisation. The percentage of participants with protective rSBA titers was high after primary immunisation but waned over the following 6 years. A single booster at the age of 7 years or older seems to prolong protection for several years.CONCLUSIONS:
A single dose of MenC or MenACWY vaccine at 12-23 months of age provides robust protection against MenC IMD. Data on booster immunisation are sparse, but indicate prolonged protection for three years at least.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Inmunización Secundaria
/
Vacunas Meningococicas
/
Infecciones Meningocócicas
Idioma:
En
Revista:
J Infect
Año:
2024
Tipo del documento:
Article